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Objective. To describe the clinicoradiological and histopathological ﬁndings in a case of lacrimal gland enlargement secondary to
lymphomatoid granulomatosis (LG) and to review the literature. Design. Case report and systematic literature review. Methods.A
75-year-old woman presented with right ptosis. Computerised tomography showed lacrimal gland enlargement, and biopsy done
was inconclusive. She subsequently developed pulmonary symptoms and underwent transbronchial biopsy that was diagnosed as
LG.PubMedandOVIDdatabasesweresearchedusingtheterm“orbit/eyeinvolvementinlymphomatoidgranulomatosis”.Articles
that predated the databases were gathered from current references. Results. The patient underwent lacrimal gland biopsy which
revealed necrotic and inﬂamed tissue with no further categorisation but transbronchial biopsy helped in establishing the diagnosis
of LG. On initiation of prednisolone and cyclophosphamide, her orbital lesion resolved but the patient died following massive
pulmonary hemorrhage within a month of diagnosis. Conclusion. Ophthalmic involvement in LG is very rare. Varied presentations
are due to central nervous system involvement, vasculitis, or inﬁltration of ocular or orbital structures. LG is an angiocentric and
angiodestructive granulomatous disorder and can involve any tissue, thus accounting for the variable presentations reported in
literature.
1.Introduction
LG is an Epstein-Barr virus- (EBV-) associated angiocentric
B-cell lymphoproliferative process. The lung is the most
commonly involved organ, but skin, central nervous system,
kidney, and gastrointestinal tract can also be involved. There
are few reports of ophthalmic involvement in LG. We report
a patient with LG who presented with dacryoadenitis and
reviewtheliteratureontheophthalmicmanifestationsofthis
condition.
2.CaseReport
A 75-year-old woman developed a painless acute right ptosis
associated with double vision and vertigo. Examination
revealed inferomedial globe displacement and an S-shaped
ptosis (Figure 1). Computerized tomography (CT) revealed
an enlarged right lacrimal gland with areas of central hypo-
density (Figure 2). The medical history included Sjogren’s
syndrome, abdominal aortic aneurysm, and colonic ade-
nocarcinoma 2 years previously that was treated surgically.
The lacrimal gland was biopsied through a superior lid
crease approach. Histopathology was inconclusive showing
only necrotic and inﬂamed tissue with granulomatous
inﬂammation (Figure 3). A further biopsy was declined by
the patient.
She subsequently developed fever, malaise, and cough. A
CT of the chest showed a necrotic mass involving her left
upper lobe and hilar vessels with a suspicious right lung
lesion. Hilar and mediastinal lymphadenopathy was noted.
CT abdomen revealed multiple hepatic lesions. She under-
went bronchial biopsy and the histopathology demonstrated2 Journal of Ophthalmology
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Figure 1: Clinical photograph showing inferomedial displacement
of the globe.
Figure 2: T1 weighted contrast enhanced MRI scan coronal
sections through the orbits showing contrast enhancing lacrimal
gland lesions with central hypodense areas.
ﬂorid necrotizing inﬂammation with palisading granulomas
and a probable diagnosis of Wegner’s granulomatosis was
made. Her blood investigations showed elevated CRP levels
(150mg/l) and anemia (Hb-10g/dl). ANCA was negative
and CEA levels were normal (2μg/L). The patient was
started on Prednisolone 25mg/day and Cyclophosphamide
100mg/day.
She was readmitted 1 month later with further deteriora-
tion of her systemic condition. CT of the orbits were normal
with complete resolution of the lacrimal gland enlargement.
However, her CT of the chest revealed development of
left lower lobe parenchymal inﬁltrates and resolution of
liver lesions when compared with the previous study. She
underwent a repeat bronchial biopsy and the histopathology
showed a polymorphous atypical lymphoid inﬁltrate of
CD20 positive B cells with positive labelling for EBV
admixed with CD3 positive T cells. The lesion displayed
focal necrosis and focal angiocentricity and a diagnosis of LG
with areas of high grade involvement was made (Figure 4).
MicrobiologyyieldedStaphylococcusaureus.Shewastreated
with antibiotics and steroids and cyclophosphamide. She
underwent bone marrow biopsy which showed reactive
lymphoid aggregates but ruled out lymphoma. Patient
continued to deteriorate and died 1 month later due to
massive pulmonary hemorrhage.
Figure 3: Photomicrograph of lacrimal gland biopsy shows a
lympho-histiocyticinﬁltratewithreactive ﬁbroblasts(hematoxylin-
eosin, original magniﬁcation ×400).
(a) (b)
(c) (d)
Figure 4:Transbronchialbiopsy.(a)Photomicrographofthetrans-
bronchial biopsy demonstrates submucosal lymphocytic inﬂamma-
tory inﬁltrate (hematoxylin-eosin, original magniﬁcation ×100).
(b) Higher magniﬁcation shows a polymorphous lymphoid pop-
ulation with atypical lymphoid cells (hematoxylin-eosin, original
magniﬁaction ×400). (c) Immunohistochemistry illustrates that
the cells are predominantly B-cells (CD20 immunohistochemical
stain, original magniﬁcation ×200). (d) Immunohistochemistry for
Epstein-Barr virus antigen demonstrates positive staining (EBV-
LMP immunohistochemical stain, original magniﬁcation ×400).
3. Discussion
LG was ﬁrst described by Leibow et al. [1] in 1972 as
an atypical angiocentric and angiodestructive lymphopro-
liferative disease involving lungs as well as other extra
nodal sites, mainly skin, CNS, and kidneys. In recent
years it has been shown to be a T-cell rich EBV-related
lymphoproliferative disease [17]. It can present at any age
although 80% of the cases occur between 4th and 6th
decades. The incidence is higher in men with a male-to-
female ratio of 1.7:1 [3]. As with other EBV-associated lym-
phoproliferative disorders (such as post-transplant lympho-
proliferative disorder), LG occurs with increased frequencyJournal of Ophthalmology 5
in immunosuppressed patients. In its most indolent forms,
it presents with pulmonary/skin nodules in an otherwise
asymptomatic patient that resolve without any treatment.
Fewer than 20% of the patients present with eye involve-
ment, hepatosplenomegaly, adenopathy, and arthralgia [18].
Around 14–27% of the patients achieve durable remissions
without treatment though a more likely course is that of
relentless progression with multiple organ involvement and
progression to large-cell lymphoma with a median survival
of 14 months [3].
LG is characterized histologically by a polymorphic
lymphoid inﬁltrate consisting of mature lymphocytes,
eosinophils, histiocytes, and atypical lymphoreticular cells
[1]. Focal areas of necrosis and transmural inﬂammation of
vessels (angiitis) are also typical and extensive necrosis and
monomorphic large-cell lymphoid inﬁltrate are indicative
of a high-grade lesion. Since the histological ﬁndings are
highly reminiscent of Wegener’s granulomatosis, a much
more common condition, the diagnosis of LG needs to be
conﬁrmed by demonstrating the presence of EBV positive
B-cells within the lesion. A 3-tier grading system has been
proposed based on the number of EBV positive cells [19].
The histological grading may vary over time or from site
to site [18] and hence multiple site or repeated biopsies are
essential to establish the diagnosis in cases with high index of
clinical suspicion.
No well-studied eﬀective treatment exists for this disease.
Traditional treatment regimens were centered on immuno-
suppression (with cyclophosphamide and prednisolone) [5]
but since the recognition that LGY is an EBV driven
disease, antiviral therapy in the form of interferon-alpha
is increasingly employed [18]. Combination chemotherapy
is reserved for high-grade lesions. Newer therapies such as
rituximaband autologousstemcelltransplantation have also
given good results [19–21]. Radiotherapy has also been used
in certain cases [2] ,a n dp r o v e nt ob ea ne ﬀective adjunct in
treating localized disease.
The reports of ophthalmic involvement in LG [1–16, 22,
23]h a v eb e e ns u m m a r i z e di nT a b l e1. Twenty one cases
were reviewed. Four cases were excluded because suﬃcient
information was not available [3, 5]. Excluding these cases,
details of the remaining 17 cases were obtained and the age
of onset, sex, ophthalmic presentation, the tissue biopsy used
toestablishdiagnosis,treatment,andoutcomewereassessed.
The age at presentation ranged from 7 to 75 years
(mean: 43.9 years) with equal incidence in both sexes: (9
male:9 females). Of the 18 cases including our case, six
presented with ocular symptoms while the remainder had
pulmonary symptoms or central nervous involvement at
initial diagnosis. The ophthalmic manifestations were due
to inﬁltration of the ocular and orbital tissues in 12 cases;
vasculitis caused functional disturbances in 3 cases; and
ophthalmic expressions of the disease were seen in 4 cases
from CNS disease. Eight of the 18 cases (44.4%) presented
acutely with progressive development of ocular manifesta-
tions within a month. The diagnosis was established in most
cases by lung biopsy (13 cases). Only 4 cases had oph-
thalmic manifestations secondary to central nervous system
(CNS) involvement (including diplopia, ptosis, nystagmus,
and tonic pupil) contrary to earlier reports that ocular
involvement in LG is commonly due to CNS involvement
[23].
Five cases were treated with radiotherapy for the ocular
manifestations. These included orbital inﬁltrations, eyelid
swelling, and one case of conjunctival involvement, with
all cases showing very good response with regression of
symptoms. The remaining cases were treated with corti-
costeroids and/or immunosuppressants and in all cases the
ocular manifestations resolved partially or completely except
cases of optic neuropathy and optic nerve infarction. The
follow up period for the cases ranged from 6 weeks to twelve
years (mean = 3.15 years). Of the 17 cases where follow up
information was available, 8 succumbed to the disease with a
median survival of 6 months (range: 6 weeks to 2 years).
In our case, the CT of the orbit revealed a nonhomoge-
nous enlargement of lacrimal gland with central hypodense
areas which corresponded with areas of necrosis within
the lacrimal gland. This feature was of notable signiﬁcance
as the diﬀerential diagnoses included very few conditions
such as necrotic or cystic changes within a pleomorphic
or mucoepidermoid tumor of lacrimal gland and acute
dacryoadenitis with abscesses within the gland [24–26].
Though ophthalmic manifestations are uncommon, they
mayrarelybethepresentingfeatureinLG.Ophthalmologists
should be aware of this condition, especially since many of
the manifestations can mimic those of Wegener’s granulo-
matosis. It is also a condition which may require multiple
tissue biopsies to establish the diagnosis and one should
not hesitate to do so in cases with high index of clinical
suspicion. Given the systemic nature of the disease and poor
prognosis of late-stage high-grade lesions, early diagnosis
and appropriate treatment by an expert with an interest in
this condition may oﬀer the best hope for the patient.
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